Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

ANI Pharmaceuticals Forecasts 2024 Adjusted EPS Of $4.38-$4.82 Versus Prior Guidance Of $4.26-$4.67 And Consensus Of $4.49

Author: Benzinga Newsdesk | August 06, 2024 07:03am

Revised Full Year 2024 Guidance:

The following guidance for 2024 does not include contribution from the pending acquisition of Alimera.

	Revised Full Year 2024 Guidance	Prior Full Year 2024 Guidance	2023 Actual	Growth
Net Revenue (Total Company)	$540 million - $560 million	$520 million - $542 million	$486.8 million	11% - 15%
Cortrophin Gel Net Revenue	$185 million - $195 million	$170 million - $180 million	$112.1 million	65% - 74%
Adjusted Non-GAAP EBITDA	$140 million - $150 million	$135 million - $145 million	$133.8 million	5% - 12%
Adjusted Non-GAAP Diluted EPS	$4.38 - $4.82	$4.26 - $4.67	$4.71	(7)% - 2%

Posted In: ANIP